ProCE Banner Activity

LAURA: Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC

Conference Coverage
Slideset

In the phase III LAURA trial, treatment with osimertinib after definitive CRT significantly improved PFS vs placebo in patients with unresectable stage III EGFR-mutated NSCLC.

Released: June 04, 2024

Expiration: June 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.